Lunai Bioworks (LNAI) Proxy filing summary

Executive summary

• Special meeting scheduled for May 4, 2026, to vote on a reverse stock split and potential adjournment.

• Reverse stock split proposed at a ratio between 1-for-3 and 1-for-30, with the exact ratio to be set by the board.

• Main goal is to increase share price to maintain Nasdaq listing and improve marketability and liquidity.

• Board retains discretion to implement or abandon the split within one year of approval.

• No current plans to issue additional shares resulting from the split, but reserves right for future corporate purposes.

Voting matters and shareholder proposals

• Proposal 1: Approve amendment for reverse stock split; board recommends voting FOR.

• Proposal 2: Approve adjournment of the meeting if more time is needed to solicit votes; board recommends voting FOR.

• Voting standards depend on Nasdaq listing status at the time of the amendment; could require majority of all outstanding shares if delisted.

• Abstentions and broker non-votes generally have no effect on Proposal 1; abstentions count as AGAINST for Proposal 2.

Board of directors and corporate governance

• Board has full discretion to select the reverse split ratio and timing within the approved range.

• No director, executive officer, or nominee has a substantial interest in the proposals beyond their shareholdings.